bluebird bio (BLUE) Tops Q4 EPS by 76c, Updates on BLA Submission for Lovo-Cel for Sickle Cell Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to bluebird bio (BLUE) Tops Q4 EPS by 76c, Updates on BLA Submission for Lovo-Cel for Sickle Cell Disease

bluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Operational Progress

March 29, 2023 7:00 AM EDT

- Continued strong commercial launch for ZYNTEGLO® and SKYSONA®; 7 patient starts (cell collections) across both programs to date -

- Update on Biologics License Application (BLA) submission for lovo-cel for sickle cell disease (SCD) -

- Management to host conference call today, March 29, 2023 at 8:00AM ET -

SOMERVILLE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (NASDAQ: BLUE) (bluebird bio or the Company) today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2022 including recent... More